Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PROCEPT BioRobotics Corporation (PRCT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. PROCEPT BioRobotics is a surgical robotics company in urology, listed on The Nasdaq Global Market under the symbol PRCT, and its filings offer detailed information on business operations, financial performance, risk factors, and governance.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from AQUABEAM and HYDROS Robotic Systems, segment details such as U.S. and international revenue, gross margins, operating expenses, and liquidity. Current reports on Form 8-K include items such as quarterly financial results, changes to executive compensation arrangements, and other material events affecting the company.
Through this page, users can also track executive and director compensation arrangements and changes to severance or change-of-control agreements, as disclosed in 8-K exhibits. While insider transaction reports on Form 4 are not listed in the excerpts above, Stock Titan’s filings interface is designed to surface such ownership changes when available, alongside 10-K, 10-Q, and 8-K filings.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, helping readers quickly understand topics such as revenue trends, installed base growth, non-GAAP measures like Adjusted EBITDA, and risk factor highlights. Real-time updates from the SEC’s EDGAR system ensure that new PRCT filings appear promptly, allowing investors, analysts, and researchers to follow PROCEPT BioRobotics’ regulatory and financial reporting history in one place.
Procept Biorobotics Corp ownership update: FMR LLC (with Abigail P. Johnson listed) reports beneficial ownership of 1,610,138.49 shares, representing 2.9% of Procept Biorobotics common stock on Schedule 13G/A (Amendment No. 5).
The filing lists sole dispositive power for FMR LLC of 1,610,138.49 shares and states that no other single person holds more than 5% of the class. Signature blocks show authorization via power of attorney.
PROCEPT BioRobotics Corporation reported that its board of directors increased in size from eight to nine members and appointed Daniel Puckett to fill the new seat. He is a Class III director, with an initial term running until the 2027 annual meeting of stockholders.
The board determined that Puckett qualifies as an independent director under SEC and Nasdaq rules and appointed him to the Audit Committee, effective immediately. He is a former Chief Financial Officer of Shockwave Medical, Counsyl and Ariosa Diagnostics, and will receive compensation consistent with other non‑employee directors.
PROCEPT BioRobotics Corporation filed its annual report detailing its surgical robotics business focused on treating benign prostatic hyperplasia (BPH) with its AquaBeam and HYDROS robotic systems. Revenue grew to $308.1 million in 2025 from $224.5 million in 2024, while net loss was $95.6 million, with an accumulated deficit of $641.6 million.
As of December 31, 2025, the company had an installed base of 912 systems globally, including 718 in the United States. Management cites an estimated $30 billion U.S. addressable market for Aquablation therapy and highlights broad reimbursement coverage that it estimates reaches about 95% of U.S. men.
The report emphasizes extensive clinical data supporting Aquablation therapy, growing international presence, ongoing prostate cancer clinical trials, and continued investment in R&D, AI-enabled features, and sales and marketing to expand system placements and procedure volumes.
PROCEPT BioRobotics used its Investor Day to outline rapid growth in Aquablation therapy for benign prostatic hyperplasia and a clearer path to profitability. Total revenue grew from
The company is rolling out the next-generation HYDROS robotic platform, reorganizing its commercial model with dedicated launch teams, and investing heavily in clinical evidence, including the pivotal WATER IV prostate cancer trial. For 2026, it guides revenue of
PROCEPT BioRobotics Corp executive receives stock from performance award
EVP and Chief Legal Officer Nouri Alaleh acquired 4,872 shares of PROCEPT BioRobotics common stock through a grant at a price of $0.00 per share. After this award, Alaleh directly holds 77,345 common shares.
The shares represent common stock underlying a portion of previously granted performance stock units. The company’s Compensation Committee certified on February 19, 2026 that required performance goals were achieved, causing these units to be deemed earned. The earned shares are scheduled to vest on March 5, 2026, with each unit corresponding to one share of common stock.
Waters Kevin reported acquisition or exercise transactions in this Form 4 filing.
PROCEPT BioRobotics Corp EVP and CFO Kevin Waters was granted 3,532 shares of common stock through earned performance stock units. The Form 4 shows these shares at a price of $0.0000 per share, reflecting an award rather than an open-market purchase or sale.
The award represents a portion of previously granted performance stock units that became earned after the compensation committee certified achievement of preset performance goals on February 19, 2026. These earned units are scheduled to vest on March 5, 2026, and each unit corresponds to one share of common stock, bringing Waters’ direct holdings to 111,523 shares after the transaction.
PROCEPT BioRobotics reported strong growth but wider losses for 2025 and reset its 2026 outlook. Q4 2025 revenue was $76.4 million, up 12%, with about 12,200 U.S. procedures and 65 new systems placed. Full-year 2025 revenue reached $308.1 million, a 37% increase, and gross margin improved to 64%, but net loss expanded to $95.6 million.
The U.S. install base grew 42% to 718 systems, while Q4 gross margin slipped to 61% due to lower-than-expected consumable revenue and a one-time field action. For 2026, the company guides revenue to $390–$410 million (27–33% growth), U.S. procedure growth of 39–48%, gross margin around 65%, operating expenses near $350 million, and an adjusted EBITDA loss between $30 million and $17 million. Cash and restricted cash totaled $289.5 million at year-end 2025.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 3,271,408 shares of PROCEPT BioRobotics Corp common stock, representing 5.9% of the outstanding class as of the reported date. T. Rowe Price has sole voting and dispositive power over all these shares.
The firm states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PROCEPT. It also expressly denies being the beneficial owner of the securities beyond what is required for this disclosure.